Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia.

PloS one - 1 Jan 2011

Leder Kevin, Foo Jasmine, Skaggs Brian, Gorre Mercedes, Sawyers Charles L, Michor Franziska

Abstract excerpt

Chronic myeloid leukemia (CML) is the first human malignancy to be successfully treated with a small molecule inhibitor, imatinib, targeting a mutant oncoprotein (BCR-ABL). Despite its successes, acquired resistance to imatinib leads to reduced drug efficacy and frequent progression of disease. Understanding the characteristics of pre-existing resistant cells is important for evaluating the benefits of first-line...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Proliferation
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fusion Proteins, bcr-abl

Share to Genetic Fitness

Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Share to Mutation Rate

Share to Protein Kinase Inhibitors

Share to Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 22140458
DOI: 10.1371/journal.pone.0027682
PMCID: PMC3225363

Genes

BCR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Fitness conferred by BCR-ABL kinase domain mutations determines the risk of pre-existing resistance in chronic myeloid leukemia.PMID 22140458Read ↗

Drug resistance in cancer: Principles of emergence and preventionSemantic proximity Read ↗

Reproductive fitness advantage of BCR-ABL expressing leukemia cells.Semantic proximity Read ↗

Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapySemantic proximity Read ↗

Data and implication based comparison of two chronic myeloid leukemia models.Semantic proximity Read ↗

Multi-scale Predictions of Drug Resistance Epidemiology Identify Design Principles for Rational Drug Design.Semantic proximity Read ↗

Predicting Minimal Residual Disease in Acute Myeloid Leukemia through Stochastic Modeling of ClonalitySemantic proximity Read ↗

Dark selection for JAK/STAT-inhibitor resistance in chronic myelomonocytic leukemiaSemantic proximity Read ↗

Differential response to cytotoxic therapy explains treatment dynamics of acute myeloid leukaemia patients: insights from a mathematical modelling approachSemantic proximity Read ↗

Computational tools for assessing gene therapy under branching process models of mutation.Semantic proximity Read ↗

Mathematical modeling of JAK2V617F clonal expansion in a general population cohort.Semantic proximity Read ↗

Interplay of mutations, alternate mechanisms, and treatment breaks in leukaemia: Understanding and implications studied with stochastic models.Semantic proximity Read ↗

Molecular dynamics reveal BCR-ABL1 polymutants as a unique mechanism of resistance to PAN-BCR-ABL1 kinase inhibitor therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.